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ABSTRACT
Glucuronide conjugates of soy isoflavone metabolites genistein, daidzein, glycitein and equol in urinary samples from women,
female pigs and female rats were pretreated with methanol instead of solid phase extraction or liquid-liquid extraction after
enzymatic digestion. The samples were analyzed using an LC-ESI-MS/MS ion trap system. Analysis of rat liver sample using this
procedure was also attempted. By comparison the elution sequences with results from previous studies, glucuronide conjugates
including 7-gluc-Dai, 7-gluc-Gly, 4’-gluc-Dai, 7-gluc-Gen, then 4’-gluc-Gen were identified sequentially in women urine. However,
5-gluc-Gen was also observed in female porcine urine. In rat urine, sul-Dai was observed after 7-gluc-Dai, while 7-gluc-Equ and
4’-gluc-Equ were observed after 7-gluc-Gen. The metabolite profiles in rat liver tissue samples were found with 7-gluc-Dai and 7gluc-Gen. However, glucuronide conjugates of equol and sulfate conjugate of daidzein were only found in rat urine. Interestingly,
quantification studies performed by LC-APCI/MS and LC-ECD showed that the aglycone and conjugated glycitein were both found
in porcine and rat urine, but only conjugated glycitein was found in woman urine.
Key words: methanol pretreatment, urine, tissue, glucuronide conjugate

INTRODUCTION
Both beneficial and adverse effects of soy isoflavone
metabolites (SIM) after soy dietary by ingesting soy products such as soy foods or soy protein isolates or by intaking of soy isoflavone supplements have been reported
since last decades(1-14). Among the SIM, genistein, daidzein, equol, and O-desmethylangolensin (O-DMA) were
reported as the major SIM found in human urine after
soy diet(15,16). Other related SIM such as dihydrogenistein (DHG), dihydrodaidzein (DHD) were also reported
with traceable physiological effects. Glycitein was the
major soy isoflavone from food resource along with genistein and daidzein without significant recognition for its
effects(15-17). Genistein, the most studied soy isoflavone,
was reported to be the major bioactive isoflavone with
anti-angiogenesis activity(18,19), as a tyrosine kinase inhibitor (20), and a growth inhibitor for human breast cancer
cells(21). However, equol, the intestinal microbial metabolite of daidzein, was found the highest level with the
largest variation compared to genistein, daidzein and ODMA in human urine three days after soy diet consumption in human studies(22,23). In a previous study, equol
was known to be more estrogenic compared to dadizein
* Author for correspondence. Tel: +886-4-23323456 ext. 1831;
Fax: +886-4-23305834; E-mail: hebronchang@asia.edu.tw

and O-DMA(24). In breast cancer resistant chimpanzees,
enormous amount of urinary equol, equal to 6 times of
urinary daidzein, was also detected in urine samples (25).
It was proposed that equol was a very important bioactive
compound that was transformed from daidzein in equolproducing population for the evaluation for chemoprevention and clinical effectiveness of soy protein in cardiovascular, bone and menopausal health benefits(26).
Varieties of SIM including aglycones, glucuronide and sulfate conjugates were detected in the urine of
human consuming soy diet (27). It was reported that the
conjugated forms were the major isoflavone metabolites
excreted in men and women subjects (27). In the previous studies, conjugated forms of isoflavones in human
urine were obtained through the calculation of values
after enzymatic digestion with a mixture of sulfatase
and/or β-glucuronidase followed by diethyl ether extraction. This method was commonly used for finding the
values of isoflavone conjugate forms in human fluids (2739)
and in rat fluids (40-49). Conjugated forms of genistein
and daidzein were observed by high performance liquid
chromatography along with radioisotope chemistry and
mass spectrometry in rat urine (39) and in human and rat
plasma (15,44,45). In an incubation of genistein or daidzein
with either bovine hepatic or recombinant human uridine
diphosphate glucuronosyltransferases (UGT) in the pres-
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ence of uridine diphosphate glucuronic acid (UDPGA),
glucuronide conjugates of genistein and daidzein at 7and 4’- position were observed. These isoflavone metabolites were also identified using liquid chromatography
mass spectrometry (LC/MS) in the plasma of human
subjects consuming soy tablet (15). In the pooled urine of
rats fed with soy diet, a series of glucuronide conjugates
of soy isoflavone metabolites were characterized (45). An
analytical method was established to measure the intact
phytoestrogen conjugates in human urine using liquid
chromatography electrospray ionization tandem mass
spectrometry (LC-ESI-MS/MS) with stable labeled [13C3]
isoflavones for quantification for isoflavone metabolites (48). General identification methods used for aglycones and conjugates of soy isoflavoens were based on
mass spectrometric analysis either without pretreatment
which might cause handling problems for instrumentation or with complicated procedures such as enzymatic
digestion and solid phase extraction which might be time
consuming and economically costly (27-49). Methanol
pretreatment may reduce the problems caused by previous
mentioned methodology. In this study, methanol extraction was used to clean up samples before identification
of isoflavone metabolites from woman, porcine, and rat
urine and liver samples. LC-ESI-MS/MS ion trap system
was also established to compare urinary soy isoflavone
profiles from the subjects. Quantification of isoflavone
metabolites of human, porcine and rat urine was applied
by liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry (LC-APCI/MS) system
and liquid chromatography and electrochemical detection
(LC-ECD) system as previously mentioned(17,28,29).

MATERIALS AND METHODS
I. Chemicals
Daidzein (7,4’-dihydroxyisoflavone), genistein (7, 5,
4’-trihydroxyisoflavone), equol (7,4’-isoflavandiol), and
glycitein (7,4’-dihydroxy-6-methoxyisoflavone) were
purchased from Indofine Chemical Co., Inc. (Somerville,
NJ, U.S.A.). Dihydrodaidzein (7, 4’-dihydroxyisoflavanone, DHD), dihydrogenistein (7, 5, 4’-trihydroxyisoflavanone, DHG) and O-desmethylangolensin (1-(2, 4dihydroxyphenyl)-2-2(4-hydroxyphenol)-propan-1-one,
O-DMA) were purchased from Plantech (Reading, U.K.).
All other chemicals used for LC-MS/MS analysis were
purchased from Sigma (St. Louis, MO, U.S.A.). Soy
protein isolate (SPI) was a gift from Protein Technologies
International (St. Louis, MO, U.S.A.).
II. Sample Collection and Preparation
Human subjects were treated as previously
described(16), and three women urine samples were used in
this study. Female urine samples from 9 Sprague-Dawley

rats (0.5 mL of each subject) collected from a previous
study(17) were also used. Porcine urine samples from two
3-days-old female pigs fed isoflavone-free diet for 14 days
then changed to diet containing 24% soy protein isolates
(SPI) for 4 days, were collected. The urine samples were
collected between 6 and 9 am after the 4th day of SPIdiet, and were placed in tubes containing ascorbic acid
and sodium azide (0.1% of each) and stored at -20°C until
analysis. Human and porcine urinary samples, and pooled
rat urine (2 mL for each study) were added with 8 mL of
methanol, vortexed for 30 sec, and ultrasonicated for 10
min. Samples were then centrifuged at 2,000 rpm for 5
min at 4°C. This procedure was repeated once and supernatants were pooled in 45 mL tubes and dried in a SC210A
Speedvac plus (Thermo Savant, Holbrook, NY, U.S.A.) for
overnight at room temperature. Samples were reconstituted in 50% methanol before analyzed by LC-ESI-MS/MS.
III. LC-ESI-MS/MS Analysis
Concentrated urine samples with 10 µL injections
were analyzed in a Bruker model Esquire LC multiple
ion trap system (Bruker Daltonics Inc. Billerica, MA,
U.S.A.) equipped with a 250 × 4.6 mm i.d., 5 µm, Luna
C18(2) column (Phenomenex, Torrance, CA, U.S.A.).
The solvent system consisted of solution A (0.1% formic
acid in water, v/v) and solution B (0.1% formic acid in 1:3
acetonitrile: methanol, v/v). The solvent was delivered
with flow rate of 1 mL/min by Agilent 1100 series liquid
chromatographer, with splitter unit of 1:10, in a linear
gradient of B from 8% to 25% B in 35 min, then to 45%
in 25 min. The gradient was then changed from 45% B to
55% B in 10 min, and then to 100% B in 10 min. Solvent
B was held at 100% B for 15 min and then returned to 8%
B in 5 min. The metabolites were analyzed using a photodiode array detector with a wavelength range between
200 nm and 350 nm. The samples were analyzed for at
least 3 times in a negative mode with a capillary voltage
of 4 kV, a nebulizer pressure of 35 psi, and a drying gas
flow of 10 mL/min at 350°C. The MS scan range was
between 50 and 700 m/z with 50% of compound stability
and 50% of trap drive level. The standards of glucuronide conjugates of daidzein and genistein were checked
using liver cell media incubated with genistein and daidzien (unpublished data). The serial eluted conjugated
metabolites were identified by referring to the results
showed in previous studies (18, 45, 47, 48).
IV. Quantification of Isoflavone Metabolite
A modified LC-ECD method (28,29) and an LCAPCI/MS method(16,17,29) were applied to quantify the
isoflavone metabolites in sample extracts after enzymatic digestion as mentioned previously(29). The detector settings for LC-ECD analysis were 400, 450, 480,
520, 580, 630, 680, and 730 mV. Genistein, daidzein and
glycitein were monitored at 480 mV and equol at 580 mV.
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RESULTS AND DISCUSSION
In this study, the profiles of isoflavone metabolites
in woman, female porcine and rat urine samples were
analyzed using an LC-ESI-MS/MS ion trap system with
negative ion mode and monitored with UV (λ=260 nm
for genistein, daidzein and equol; λ=280 nm for glycitein) detector (Figure 1A). Two isoflavone metabolites
eluted at 46.2 and 52.8 minutes with extracted ion chromatogram (EIC) of m/z=429 in a negative mode from
woman urine samples were shown in Figure 1B. LC-ESIMS/MS profile appeared that the molecular ion [M-H] at m/z =429 observed in both peaks yielded two product
ions at m/z =253 and m/z =175, which represent glucuronide-conjugate of daidzein, fragments of daidzein aglycone and glucuronic acid, respectively (data not shown).
These two eluted compounds were identified as 7-glucuronide-daidzein (7-gluc-Dai) and 4’-glucuronide-daidzein (4’-gluc-Dai)(45, 48) (Table 1).
Another compound eluted at 48.3 min with EIC of m/
z =459 (Figure 1C) from the woman urine sample yielded
two product ions with m/z = 283 and 175 (data not shown).
These ions represent glucuronide-conjugated glycitein,

glycitein and glucuronic acid in a negative mode. This
compound was thus identified as 7-glucuronide-glycitein
(7-gluc-Gly) according to the fragmentation results (45, 48).
The compounds eluted at 54.2 min and 59.6 min
with EIC of m/z =445 (Figure 1D) from urinary samples
were identified as glucuronide-conjugates of genistein.
The parent compound at m/z 445 yielded two product
ions at m/z =269 and 175 (data not shown) which represented genistein and glucuronic acid respectively. These
compounds were identified as 7-glucuronide-genistein (7gluc-Gen) and 4’-glucuronide-genistein (4’-gluc-Gen)(48).
Results from a quantification study showed that glucuronide conjugates of daidzein, glycitein and genistein were
identified along with their aglycone formed by calculation after enzymatic hydrolysis in woman urine.
In female porcine and rat urine, the patterns of
urinary profile were found similar to those of woman
urinary profile. Glucuronide conjugates of daidzein,
genistein and glycitein were identified as 7-gluc-Dai, 4’gluc-Dai, 7-gluc-Gly, 7-gluc-Gen and 4’-gluc-Gen. Interestingly, a minor peak eluted at 60.4 min which was not
clearly observed in woman urine was also identified with
EIC of m/z =445 and product ions with m/z =269 and m/z
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Figure 1. LC-ESI- MS/MS profile of woman urine. 
(A) Woman urinary samples were monitored by UV absorbance at λ=260 nm, and were identified using extracted ion chromatogram (EIC)
and automatic MS/MS with negative mode, (B) Two glucuronide conjugates of daidzein at EIC 429 were eluted at 46.2 and 56.8 min, (C)
Glucuronide conjugate of glycitein (EIC 459) was eluted at 48.3 min (monitored at λ=280nm), (D) Two glucuronide conjugates of gensitein
(EIC 445) were eluted at 54.2 and 59.6 min.
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Table 1. Retention times, mass of extracted ion chromatogram (EIC) and automatic MS/MS of observed urinary conjugated metabolites in
women, female pigs and rats
Isoflavone metabolite
conjugates

RT
(min)

EIC MS
(m/z)

Product ions
(m/z)

Women

Pigs

Rats

7-glucuronide-Daidzein

46.2
(260 nm)

429

253,175

+

+

+

Sulfate-Daidzein

46.7
(316 nm)

333

253

N/A

N/A

+

7-glucuronide-Glycitein

48.3
(280 nm)

459

283,175

+

+

+

4’-glucuronide-Daidzein

52.8
(260 nm)

429

253,75

+

+

+

7-glucuronide-Genistein

54.2
(260 nm)

445

269,175

+

+

+

7-glucuronide- Equol

56.5
(260 nm)

417

241,175

N/A

N/A

+

4’-glucuronide- Equol

56.9
(260 nm)

417

241,175

N/A

N/A

+

4’-glucuronide-Genistein

59.6
(260 nm),

445

269,175

+

+

+

5-glucuronide-Genistein

60.4
(260 nm)

445

269,175

N/A

+

+
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Figure 2. LC-ESI- MS/MS profile of female rat urine.
(A) Female rat urine samples were monitored by UV absorbance at λ=316 nm, and were identified using extracted ion chromatogram (EIC) and
automatic MS/MS with negative mode. Sulfate conjugates of daidzien at EIC 332.9 was eluted at 46.7 min, (B) Product ion mass spectra of
sul-daid (m/z=332.9).
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Figure 3. (A) LC-ESI- MS/MS profile of glucuronide conjugates of equol (gluc-Equ), (B) Female rat urinary sample eluted at 56.5 and 56.9
min were monitored by extracted ion chromatogram (EIC) mode at m/z=417.0 (middle panel), (C) Product ion mass spectra of gluc-Equ (m/
z=417.0) monitored by automatic MS/MS with negative mode.

=175. This compound was putatively identified as 5-glucuronide-genistein (5-gluc-Gen)(45, 48).
In rat urine, a compound monitored under λ=316 nm
and eluted at 46.7 min with m/z =332.9, yielded a product ion at m/z =252.6 was identified as a sulfate conjugate
of daidzein (Figure 2). Interestingly, glucuronide-conjugated equol (gluc-Equ) observed at 56.5 and 56.9 min
with m/z =417 were only found in female rat urine. In an
automatic MS/MS monitoring with negative mode, these
compounds yielded two daughter ions at m/z =241 (equol)
and m/z =175 (glucuronic acid). These metabolites were
putatively identified as 7-glucuronide–equol (7-gluc-Equ)
and 4’-glucuronide–equol (4’-gluc-Equ) (Figure 3).
After enzymatic digestion, quantitative studies were
performed by LC-ECD and LC/MS analysis(16,17,28,29).
Results showed that daidzein metabolites (71.1%), compared
with genistein (14.2%), glycitein (14.8%), were the major
components of total soy isoflavones found in woman urine.
Daidzein, genistein and glycitein conjugates were about
97.6%, 91.4% and ~100% of total aglycones, respectively
in women urine. In female porcine urine, daidzein metabolites (41.5%) and genistein metabolites (39.7%) were considered as the major components of total isoflavones. Isoflavone conjugates of daidzein, genistein and glycitein were

80.5%, 82.4%, and 84.5% of total aglycones respectively.
Equol was not detected in either woman or female porcine
urine. In female rat urine, equol was a dominant isoflavone
metabolite (~72.0% of total isoflavones); daidzein, genistein and glycitein were found with 15.7%, 6.6% and 5.8% of
total isoflavones respectively. The glucuronide conjugated
equol was also observed in rat liver samples after the same
sample preparation procedure mentioned previously. The
conjugated forms of equol, daidzein, genistein and glycitein were 52.7%, 43.0%, 69.5%, and 27.6% of total aglycones
respectively as previously shown(49). UV chromatograms
showed that indeed aglycones were not observed in woman
urinary samples, however, aglycones of gensitein, daidzein,
glycitein and equol were observed in pig urinary samples,
and in rat urinary and liver samples. The urinary profile of
isoflavone metabolites in woman was very similar to that in
female pig in characterization (data not shown).
In conclusion, the elution sequence of conjugates of
isoflavone metabolites was assigned as following: 7-glucDai (46.2 min; λ=260nm), sul-Dai (46.7 min; λ=316nm),
7-gluc-Gly (48.3 min; λ=280nm), 4’-gluc-Dai (52.8 min;
λ=260nm), 7-gluc-Gen (54.2 min; λ=260nm), 7-gluc-Equ
(56.5 min; λ=260nm), 4’-gluc-Equ (56.9 min; λ=260nm), 4’gluc-Gen (59.6 min; λ=260nm), then 5-gluc-Gen (60.4 min;
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λ=260nm) (Table 1). Similar pattern was also supported by
other studies(45, 48). As shown in previous study, isoflavone
aglycones were rarely observed in woman urine. However, these algycones were observed in animal samples after
enzymatic hydrolysis using sulfatase H-5(17) as accounted
for total aglycones. These results were consistent with
previous studies(16,17,20,35,49). These glucuronide conjugated
isoflavone metabolites including 7-gluc-Dai, 4’-gluc-Dai, 7gluc-Gly, 7-gluc-Gen, and 4’-gluc-Gen were also identified
in rat urine(45) and human urine(48). 7-glucuronide conjugated gensitein (7-gluc-Gen), 4’-sulfate-genistein (4’-sulpGen) and a mixed conjugated genistein 4’-sulfate 7-glucuronide (4’-sulp-Gen-7-gluc-Gen) in urine were obtained from
rats 24 hr after oral administration of 100 ppm genistein as
described previously(17). Isomers of genistein glucuronide
conjugates (7-, 4’-, and 5-gluc-Gen), daidzein glucuronide
conjugates (7- and 4’-gluc-Dai), glycitein glucuronide conjugates (7- and 4’-gluc-Gly), and equol glucuronide conjugates
(7- and 4’-gluc-Equ) in rat urine were also obtained from
female rat 24 hr after ingestion of soy protein isolate (SPI)
(45)
. 7-gluc-Dai, 4’-gluc-Dai; 7-gluc-Gen and 4’-gluc-Gen
were observed and identified from the incubations of bovine
hepatic UGT with genistein and daidzein by LC/MS and
1
H-NMR(18,47). It was shown that daidzein and genistein
glucuronide conjugates eluted with a sequence of 7-glucDai, 4’-gluc-Dai, 7-gluc-Gen, and 4’-gluc-Gen(18,48). Interestingly, a 5-glucuronide-genistein conjugate (5-gluc-Gen)
was eluted after 4’-gluc-Gen and identified in this study and
also in rat urine(45). However, a peak eluted with similar
flow sequence was reported as an unknown compound(48).

Conjugates of O-desmethylangolensin (O-DMA), dihydrogenistein (DHG) or dihydrodaidzein (DHD) was not
observed.
Glucuronide-conjugated genistein and daidzein
observed in the present study were also identified and
confirmed from the cell media of liver cell cultures with
incubations of gensitein and daidzein for 24 hr (unpublished data). In human studies, glucuronide and/or sulfate
conjugates of genistein and daidzein were observed in
human urinary samples only by quantification analysis
after enzymatic hydrolysis (16-18,48). A sulfate conjugate
of daidzein was observed in rat urine without enzymatic treatment in this study, however, this compound was
only monitored at λ=316 nm by UV detector. Although
sulphate conjugated genistein and daidzein were identified as mentioned in previous studies, these compounds
were not able to be elucidated directly without enzymatic
treatment in biological fluid. For rat urinary samples,
serial glucuronide conjugates of isoflavone metabolites
were characterized but the samples were not quantified(45). Clarke et al. applied stable isotope labeled genistein, daidzein and equol as internal standards to identify
and quantify glucuronide and sulfate conjugates of isoflavones from human urine without sample pretreatment.
Their results showed that glucuronide conjugates were
the major isoflavone metabolites in human consuming soy
diet (48). However, the mentioned method can not apply
on tissue samples due to detection limits and hardness
of sample cleaning. However, glucuronide conjugates of
equol from urinary and liver samples were observed and

Table 2. Quantification of soy isoflavone metabolites (SIM) in urinary samples
Woman
(nmol/mL)

Isoflavone

Female Rat
(nmol/mL)

Aglyconea

(Aglycone +
Conjugates)b

Daidzein
%c

0.14 ± 0.04
2.4

5.82 ± 0.33

3.49 ± 0.18
19.5

17.93 ± 0.96

45.36 ± 2.00
57.0

79.52 ± 2.29

Glycitein
%

0.00
0

1.21 ± 0.07

1.26 ± 0.08
15.5

8.13 ± 0.09

24.15 ± 0.36
72.4

33.34 ± 1.41

Genistein
%

0.01 ± 0.00
8.6

1.16 ± 0.11

3.14 ± 0.04
17.6

17.18 ± 0.75

8.91 ± 0.22
30.5

29.20 ± 0.63

Equold
%

ND

ND

ND

ND

172.83 ± 14.08
47.3

364.94 ±14.10

Sum of Observed SIM

0.15

8.19

7.89

43.24

251.25

537.00

Sum of calculated
Total conjugates
a

Female Piglet
(nmol/mL)

8.04
(98.2%)

(Aglycone +
Conjugates)

Aglycone

35.35
(81.75%)

(Aglycone +
Conjugates)

Aglycone

287.75
(53.58%)

Aglycones were measured without enzymatic digestion.
(Aglycones + Conjugates) were measured after enzymatic digestion(29) using 100 units of Sulfatase H-5 for 3 hours at 37°C;
(b - a) = concentration of calculated conjugates.
c
Percentage of aglycone = (a/b) × 100%.
d
Equol was analyzed using LC-ECD system(28, 29) .
b
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Table 3. Percentage of total soy isoflavone metabolites (SIM) in
woman, pig and rat urine

a

Woman
(%)a

Female Pig
(%)

Female Rat
(%)

Daidzein

71.1

41.5

15.7

Glycitein

14.8

18.8

6.6

Genistein

14.2

39.7

5.8

Equol

0

0

72.0

 of SIM was calculated by (aglycone + conjugates)/(sum of
%
observed SIM) *100%; data were subtracted from Table 2.

identified without considerable troublesome in this study.
Results from previous studies with enzymatic hydrolysis
showed that aglycones and conjugates of equol were only
observed in female rat and monkey urine. Conjugates of
daidzein and genistein were found as the major metabolites in woman and porcine urine, aglycones of these two
isoflavones were mainly found in monkey urine (49,50),
and there was no significant difference between aglycone
and conjugate contents in rat urine (49,50). In this study,
results from the quantitative analysis by LC-ECD and/or
LC-APCI/MS following the previous methods (16,17,28,29)
showed that almost all of the SIM found in woman urine
(98.2%) were conjugates, ~81.8% of SIM were found
conjugates in porcine urine, and ~46.4% of SIM in rat
urine were aglycone (Table 2). Percentages of glycitein
metabolites (aglycone + conjugates) observed in woman,
porcine and rat urine were 14.8%, 18.8% and 6.6% of
total observed soy isoflavone metabolites, respectively
(Table 3). Interestingly, the conjugated glycitein was
100% in human urine, 84.5% in porcine urine, and only
27.6% in rat urine (Table 2). A further study is needed to
explore this phenomenon.
In a human study, genistein, glycitein and daidzein
were observed in 24-hr urine pool after single soy meal
intake (51). Daidzein, glycitein, and genistein are uncompetitive inhibitors of recombinant cytochrome P450 2A6
(CYP2A6) catalyzed nicotine C-oxidation(52). However,
the significance of glycitein and its potential estrogenic
role is an interesting topic to study. The previous sample
treatment employed sulfates H5 to hydrolyze the metabolites and to quantify the samples under LC-APCI/MS
system in order to identify the conjugated forms. In this
study, methanol treatment offered a rapid and economical clean up method for urine sample preparation. This
method also offered a rapid and easier clean- up for tissue
samples such as liver samples. In conclusion, methanol
treatment used in this study offered a simple and rapid
way which could be applied for preparation of either
biofluids or other biomatrices before mass spectrometric study. An LC-ESI-MS/MS ion trap system to build
mass fragmentation profiles, in combination with photodiode array system to monitor the elution sequence under

various absorbance wavelengths would be an applicable
analytical methodology to analyze glucuronide conjugated metabolites, but not always the sulphate conjugates, in
biofluid and tissue samples by merely an HPLC system.
LC-ESI-MS/MS ion trap system was not attempted for
the quantification analysis for glucuronide or sulphate
conjugates of soy isoflavones since standards of conjugated metabolites were not technically and economically
available up-to-date. This study did offer a rapid, easier
and economical substitute LC-ESI-MS/MS methodology
to perform identification study, however, along with an
established quantification methodology either using an
LC/MS system(15-17, 29) or an LC-ECD system(28,29) .
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